US 12,404,227 B2
Methods of making bempedoic acid and compositions of the same
Richard Copp, Pinckney, MI (US); Mohamed Abdelnasser, New City, NY (US); Christopher M. Cimarusti, Clementon, NJ (US); Jonathan Lane, Longmont, CO (US); Michael Barkman, Louisville, CO (US); Rasidul Amin, Cary, NC (US); Arthur John Cooper, Mentor, OH (US); Damodaragounder Gopal, Highland Heights, OH (US); and Philipp Selig, Linz (AT)
Assigned to Esperion Therapeutics, Inc., Ann Arbor, MI (US)
Filed by Esperion Therapeutics, Inc., Ann Arbor, MI (US)
Filed on Aug. 16, 2023, as Appl. No. 18/450,591.
Application 18/450,591 is a continuation of application No. 17/577,829, filed on Jan. 18, 2022, granted, now 11,760,714.
Application 17/577,829 is a continuation of application No. 17/150,321, filed on Jan. 15, 2021, abandoned.
Application 17/150,321 is a continuation of application No. PCT/US2020/038622, filed on Jun. 19, 2020.
Claims priority of provisional application 62/864,873, filed on Jun. 21, 2019.
Prior Publication US 2024/0182396 A1, Jun. 6, 2024
Int. Cl. C07C 51/04 (2006.01); C07C 59/285 (2006.01)
CPC C07C 51/04 (2013.01) [C07C 59/285 (2013.01); C07B 2200/13 (2013.01)] 20 Claims
 
1. A pharmaceutical material comprising a crystalline form of the compound of formula (V):

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof;
wherein the pharmaceutical material comprises the compound of formula (V), or a pharmaceutically acceptable salt thereof, in an amount greater than 99.0% by weight based on the total weight of the pharmaceutical material; and the pharmaceutical material comprises 0.0001% to 0.15%

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof, based on the total weight of the pharmaceutical material.